Point Therapeutics Inc. has initiated a phase 2 clinical trial of the company's lead therapeutic compound, talabostat (PT-100), for treatment of advanced metastatic melanoma.
FDA Approves Retifanlimab-Dlwr for the Treatment of Metastatic or Recurrent Locally Advanced MCC
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
New TMB-001 Sub-Analysis Data Published in Clinical and Experimental Dermatology
The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice
AAD 2023 Pearls from Zoe Diana Draelos, MD
New Guidelines to Prevent Food Allergies in Pediatric Atopic Dermatitis Patients
2 Clarke Drive Cranbury, NJ 08512